Taken together the study published by Seto et al., confirmed the pronounced efficacy of EGFR TKIs in NSCLC patients harboring EGFR mutations and for the first time showed that a meaningful improvement of this therapy concept is possible by combining drugs with different mechanisms of action. This evidence concerns the gene EGFR and non-small cell lung carcinoma.